zimybe 10/40
viatris limited - ezetimibe 10mg; simvastatin 40mg; - tablet - 10mg/40mg - active: ezetimibe 10mg simvastatin 40mg excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate - primary hypercholesterolaemia zimybe is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in adult and adolescent (10 to 17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia in patients not adequately treated on a statin alone. homozygous familial hypercholesterolaemia (hofh) zimybe is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).
zimybe 10/80
viatris limited - ezetimibe 10mg; simvastatin 80mg; - tablet - 10mg/80mg - active: ezetimibe 10mg simvastatin 80mg excipient: ascorbic acid butylated hydroxyanisole citric acid monohydrate croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate - primary hypercholesterolaemia zimybe is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), triglycerides (tg), and non high-density lipoprotein cholesterol (non-hdl-c), and to increase high-density lipoprotein cholesterol (hdl-c) in adult and adolescent (10 to 17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia in patients not adequately treated on a statin alone. homozygous familial hypercholesterolaemia (hofh) zimybe is indicated for the reduction of elevated total-c and ldl-c levels in adult and adolescent (10 to 17 years of age) patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).
ezemibe
viatris limited - ezetimibe 10mg; - tablet - 10 mg - active: ezetimibe 10mg excipient: croscarmellose sodium crospovidone hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified water sodium laurilsulfate - administered with an hmg-coa reductase inhibitor (statin) or alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-c), low-density lipoprotein cholesterol (ldl-c), apolipoprotein b (apo b), and triglycerides (tg) and to increase high-density lipoprotein cholesterol (hdl-c) in adult and adolescent (10 to 17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.
ezetimibe 10mg tablets
viatris uk healthcare ltd - ezetimibe - oral tablet - 10mg
ezetimibe
generics (uk) limited - ezetimibe - tablets - 10 milligram - ezetimibe
mylan-ezetimibe ezetimibe 10 mg tablets bottle
alphapharm pty ltd - ezetimibe, quantity: 10 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; sodium lauryl sulfate; crospovidone; lactose monohydrate; croscarmellose sodium; hypromellose - primary hypercholesterolaemia,ezetimibe administered alone, or with an hmg-coa reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.,homozygous familial hypercholesterolaemia (hofh),ezetimibe, administered with a statin, is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).
mylan-ezetimibe ezetimibe 10 mg tablets blister pack
alphapharm pty ltd - ezetimibe, quantity: 10 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; sodium lauryl sulfate; hypromellose; croscarmellose sodium; crospovidone - primary hypercholesterolaemia,ezetimibe administered alone, or with an hmg-coa reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.,homozygous familial hypercholesterolaemia (hofh),ezetimibe, administered with a statin, is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).
ezetimibe 10 mg tablets
mcdermott laboratories ltd., t/a gerard laboratories - ezetimibe - tablet - 10 milligram(s) - other lipid modifying agents; ezetimibe
mylan-atorvastatin tablet
mylan pharmaceuticals ulc - atorvastatin (atorvastatin calcium) - tablet - 10mg - atorvastatin (atorvastatin calcium) 10mg - hmg-coa reductase inhibitors
mylan-simvastatin tablet
mylan pharmaceuticals ulc - simvastatin - tablet - 10mg - simvastatin 10mg - hmg-coa reductase inhibitors